Introduction
It is generally accepted that the incidence of gastric carcinoma is declining, 1 " 6 although some have argued that this decline may have resulted from refinements in diagnosis and classification of abdominal malignancies rather than being a true decline. 7 Yet even today, gastric carcinoma still counts as one of most common causes of cancer-related death, with reported overall five-year survival rates rarely in excess of 15% in most Western series, despite continuous efforts to improve diagnostic and therapeutic modalities. 8 " 12 Identification of molecular markers for predicting preneoplastic progression, and thus improving early detection, treatment, and finally prognosis, would have considerable clinical impact. This review focuses on the pathogenesis and molecular biology of gastric carcinoma, since early events bear on the detection of gastric cancer, whereas late events may influence biological behaviour and therefore may influence therapy and overall prognosis. To stress the importance of such insights, several clinical trends are discussed that may negatively influence future survival rates.
Clinical trends
In sharp contrast to the dismal prognosis of patients with advanced gastric carcinoma, the prognosis of patients with surgically-treated early gastric carcinoma (EGC), defined as carcinoma confined to the mucosa or submucosa, with or without lymph-node metastasis, is generally excellent with reported 5-year survival rates of 90-95%. 13~17 Numerous studies from Western countries have reported an increase in incidence of early gastric carcinoma over the years. This trend is usually ascribed to improved diagnostic procedures, fiberendoscopy with targeted biopsy in particular. 14 ' 18 " 21 However, many of these studies suffer from confounding factors in that they compare results of a 'pre-endoscopy' era with those in a period in which endoscopy was routinely used, or compare time periods in which different radiological techniques were used, sometimes clearly inferior to the preferred biphasic-contrast examination with drug-induced hypotony. 22 " 25 Thus it may well be that the reported increase in incidence of EGC should be ascribed to diagnostic limitations and pitfalls in the earlier study periods rather than being a true increase. 26 ' 27 Another disturbing trend with regard to the clinical management of patients with gastric cancer is the observed increase-both relative and absolute-in incidence of proximal ly-located tumours. 28 " 32 Unfortunately, the prognosis of these proximal tumours is generally poor compared to more distal tumours. Multivariate analysis has shown that this poor prognosis is caused by the majority of these tumours being of advanced T and N stage rather than by tumour sites per se. 31 ' 33 These findings appear to correlate well with the observation that proximal tumours have a greater tendency for submucosal invasion, regardless of size or histological type, than those located in the pyloric region. Although no firm explanation exists, it has been related to the presence of a thinner muscularis mucosae in the fundic region, and the presence of firmly-packed glands, which might be able to block lateral growth. 34 Finally, a third major trend has been observed which may affect the clinical management of patients with gastric cancer. As mentioned previously, the incidence of gastric carcinoma has declined. This decline in incidence primarily results from a decrease in incidence of the intestinal-type carcinoma, according to Lauren.
35 " 37 The incidence of the diffuse type, however, varies less over time or may even gradually increase. 31 The rising number of patients with diffusetype tumours may pose some challenging diagnostic and therapeutic problems. In contrast to the intestinal type, no precursor lesion of the diffuse type has been identified, implying that endoscopic-bioptic surveillance of patients at risk for developing this tumour is not feasible. 38 ' 39 Moreover, standard biopsies may be too superficial for a correct diagnosis necessitating additional endoscopic-bioptic measures. 40^2 From a therapeutic viewpoint, two striking characteristics of the diffuse type are important. First, the diffuse type has a higher propensity for intramural spread beyond the macroscopic tumour margin. This often leads to total gastrectomy in resectable cases. Second, the diffuse type has a greater tendency to spread transmurally via the serosa, which may partly explain the worse prognosis of advanced diffuse-type tumours. 43 " 50 In conclusion, it is unlikely that the detection rate of ECC will drastically improve in the (near) future. Moreover, the increase in the proportion of patients with proximal and diffuse-type tumours-both with a higher propensity for invasive growth-will in all probability have a negative effect on future overall 5-year survival rates.
Pathogenesis
Lauren divided gastric carcinoma into two main histological types, namely intestinal-and diffuse-type carcinoma. These two types differ not only in morphology, but also in clinical and epidemiological characteristics. Moreover, it is hypothesized that the diffuse type arises from the normal gastric mucosa, whereas the intestinal type is thought to be the end result of a long and sequential process leading from normal gastric mucosa via various precursor stages to overt carcinoma. One of the first clues that led investigators to hypothesize that chronic atrophic gastritis (CAG) and intestinal metaplasia (IM) were closely linked to intestinal-type gastric carcinoma was the observation that, at least in high-risk areas, a striking correlation existed between the incidence of intestinal-type carcinoma and the overall prevalence of CAG and IM. Moreover, migrants from highrisk areas to low-risk areas not only experienced a reduction of 15% in gastric cancer risk, but also a reduction in the prevalence of IM. 51 
Consistency
Although contradictory results have been reported, 107 it may be concluded from the available data that there is almost unanimous support for a causal association between H. pylori and gastric carcinoma. In particular, all cohort studies have shown a positive association.
Reversibility
At present, no data are available to show a decrease in gastric carcinoma rates after successful eradication of H. pylori. However, since the incidence of gastric carcinoma has been decreasing, it is possible that this decrease may be due to a decrease in the prevalence of H. pylori infection during the last decades. Although we do not know what these prevalence rates were some decades ago, it is intriguing that the observed increase in prevalence of H. pylori with age could be interpreted as a decreased prevalence in successive birth cohorts. 108 Another explanation might be to assume a constant rate of infection in different age groups. However, in a serological follow-up study (n = 115) with a mean interval of 11.5 years, an annual seroconversion rate of 0.3% was found, whereas antibody concentrations did not increase with age. 109 Another study reported similar findings with an annual seroconversion rate of 0.49% during 7.5 years of followup. 110 Therefore, these data favour the previous assumption that the observed increase in prevalence P. Bloketa\.
rates of H. pylori with age is due to a birth cohort phenomenon. Finally, within the realm of reversibility, data from Finland are also suggestive that H. pylori may be causally associated with gastric carcinoma. It was found that the prevalence of chronic gastritis (both atrophic and non-atrophic) had dropped by 18% on average between 1977 and 1992, showed a birth cohort phenomenon and closely followed the epidemiological downward trend of gastric carcinoma in this study period. 111 ' 112 Since H. pylori is the principal cause of chronic gastritis, it can be inferred from these findings that the common factor, underlying both time trends, is most likely a decrease in prevalence rates of H.
pylori.
Biological plausibility
If we consider the biological plausibility of H. pylori being causally involved in gastric carcinogenesis, it should be noticed that H. pylori infection induces an increase in cell proliferation rates, which normalize after successful eradication. 113 ' 114 Moreover, infection with H. pylori usually leads to a decrease in the gastric juice concentration of ascorbic acid, a potent anti-oxidant and protective factor against gastric cancer development. Possible mechanisms of action include the scavenging of nitrite, thus preventing the formation of N-nitroso compounds; inhibition of the mutagenicity of the preformed N-nitroso compounds; and the scavenging of free oxygen radicals, which are overproduced in individuals infected with H. pylori. In cases of low gastric juice ascorbic acid concentration, nitrite and nitrosamine concentrations may rise. Since N-nitroso compounds constitute some of the most potent carcinogens known to induce gastric cancer, further evidence is provided for a role of H. pylori in gastric carcinogenesis. 115 " 123 Finally, H. pylori induces an influx of inflammatory cells, especially macrophages and polymorphonuclear neutrophils, leading to the accumulation of toxic oxygen radicals, with the risk of inducing mutations. In view of the above, it may be envisioned that the DNA-damaging effects of potential carcinogenic factors may act on the gastric epithelium in a state of H. pylori-induced hyperproliferation with less scavenging capacity. As a result, the cumulative chance of somatic mutations in oncologically important genes increases, since each cell division has a finite chance of DNA synthetic error. In view of these data, it is puzzling that some areas, despite a high prevalence of H. pylori in early childhood, have a low incidence of gastric carcinoma. A possible explanation might be to consider H. pylori as a promoting factor in gastric carcinogenesis, hypothesizing that H. pylori alone is insufficient to initiate carcinoma development. 124 ' 125 In summary, whereas the pathogenesis of diffusetype carcinoma remains poorly understood, the process leading to intestinal-type carcinoma is a multistep, multifactorially-determined sequence of histopathological changes. It appears that intestinal metaplasia in this model should be replaced by type III intestinal metaplasia. Moreover, although unsolved problems remain, there is a growing body of evidence supporting a causative role for H. pylori in gastric carcinogenesis. Undoubtedly, the different outcomes of H. pylori infection result from an intricate interplay between host and bacterial factors modified by the inherent genetic susceptibility of the host and by environmental exposure to various other carcinogens such as dietary factors. 126 " 128 However, elucidation of the exact underlying mechanisms in gastric carcinogenesis will require exploration of the molecular abnormalities that almost certainly govern the complex phenotypical aspects of this process. Interestingly, cardia carcinomas appear to have the highest DNA aneuploidy rate of nearly 100%, compared to more distal tumours, and have the worst prognosis. 136 In contrast, despite a worse overall prognosis, diffuse-type carcinomas tend to be less aneuploid than intestinal-type carcinUnfortunately, additional data on the oma. [137] [138] [139] clinical utility of flow cytometry as a marker of prognosis are inconclusive. Whereas some investigators have reported no prognostic significance, others have reported the opposite. 140 
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Alterations in oncogenes ras
The human ras proto-oncogene family includes the homologous H-, K-and N-ras genes, which code for closely related 21 kDa proteins (p21 ras ). Although considered to represent a rare event in tumorigenesis, activation of the ras genes by gene amplification with enhanced (over)expression of p21 ras proteins has been described. Immunohistochemical studies on c-erbB-2 overexpression in gastric carcinomas have reported positive c-erbB-2 membrane staining in 9-38% of cases. Moreover, conflicting data exist on the prognostic significance of c-erbB-2 over-expression and on the association between c-erbB-2 over-expression and the histological type according to Lauren. 179 "
However, the results are difficult to compare, since there is wide variation in the ability of (commercially available) c-erbB-2 antibodies to detect c-erbB-2 protein over-expression in archival paraffinembedded tissue samples. In particular, polyclonal antibody A485 was found to provide the highest level of concordance with Northern and Western blot analyses as measures of c-erbB-2 gene expression. Moreover, the concomitant use of two or more antibodies yielded in part complementary findings on c-erbB-2 over-expression. 184 Yet nearly all of the former studies invariably used a single antibody other than A485. Finally, another drawback of these previous studies is that almost no early carcinomas were included, whilst the early cancers included were mostly from Asian origin. Since early carcinomas are thought to evolve into advanced carcinomas, it is questionable whether data from advanced carcinomas can be readily extrapolated to early carcinomas. As mentioned previously, it may well be that Asian and Caucasian (early) gastric carcinomas are quite dissimilar in molecular profiles, due to differences in racial background and/or geographical exposure to various carcinogens. Japanese investigators found c-erbB-2 gene amplification in 40% of (intestinal-type) carcinomas, more than twice the number in a comparable European study. 185 ' 186 Similarly, c-erbB-2 over-expression could not be demonstrated in a series of 45 Caucasian early gastric carcinomas, using polyclonal antibody A485 and monoclonal antibody 3B5.
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MDM2
Recent studies indicate that Murine Double Minute-2 (MDM2) gene amplification with concomitant MDM2 protein over-expression may negatively regulate the transcriptional activating function of wild-type p53, may overcome wild-type p53-mediated suppression of transformed cell growth, and may increase the tumorigenic potential of NIH3T3 cells. 188 " 194 Interestingly, MDM2 gene amplification/over-expression and p53 gene mutation apparently constitute two distinct, mutually exclusive, mechanisms of wild-type p53 inactivation, since MDM2 amplification and/or over-expression have only been found in sarcomas and various other tumours without p53 gene mutation. 195 " 198 Whereas data on MDM2 over-expression in gastric carcinogenesis are scant in the literature, it has been reported that MDM2 over-expression, as assessed by immunohistochemistry, apparently does not occur in early gastric carcinomas and precursor lesions. 199 Hence, it may well be that functional inactivation of p53 by MDM2 over-expression does not play a role in gastric carcinogenesis and is restricted to a subset of malignant tumours for as yet unclear reasons.
c-met
The met proto-oncogene was originally identified as an oncogene rearranged following treatment of an osteosarcoma cell line (HOS) with N'-methyl-N'-nitro-N-nitrosoguanidine (MNNG). 200 The gene, located on chromosome 7, encodes a transmembrane tyrosine kinase identified as the receptor of Hepatocyte Growth Factor/Scatter Factor (HGF/SF). 201 ' 202 HGF/SF is a unique growth factor with mitogenic and motogenic properties, as well as the ability to induce epithelial cell invasion in collagen matrices in vitro. Moreover, it appears that met/HGF also plays a role in tumour metastasis in vivo. 203 ' 204 Activation of c-met can be due to gene amplification with subsequent over-expression, to defective post-translational processing of the precursor protein or due to oncogenic rearrangement between two distinct genetic loci, namely tpr and met, leading to a novel 5.0 kb hybrid RNA transcript encoding a 65 kDa fusion protein. 205 " 207 Several observations suggest that c-met may play a role in gastric carcinogenesis. First, amplification with concomitant over-expression of c-met has been observed in the gastric carcinoma cell line GTL-16. Second, amplification/over-expression of c-met has been reported to occur in up to 50% of gastric carcinomas. 208 " 210 Third, the tpr -met oncogenic rearrangement has been found in gastric carcinoma and its precursor lesions. Despite small numbers included, tpr -met RNA was present at all stages of the carcinogenic process. 
c-myc
Data on the c-myc gene, which encodes a nuclear transcriptional factor, are scant. Yet, although rare, both c-myc amplification and over-expression have been reported in up to 1 1 % of gastric carcinomas (n = 19) and in up to 19% of xenografts in nude mice (n = 16 
Concluding remarks
Despite advances in diagnostic and therapeutic mod- 
